JAM3 as a Prognostic Biomarker in Muscle-Invasive Urothelial Carcinoma: Correlation With Therapeutic Response, and Survival Outcomes

NCT06901934 | Not Yet Recruiting

• 1 other identifier: JAM3 biomarker bladder cancer
• Study Type: observational
• Target: 40
• Locations: 0 countries
• Sites: N/A

Brief Summary

Bladder cancer(BC) is the 10th most common cancer globally, with a higher incidence in males than females, being the 6th most common cancer in men with high mortality, causing a societal burden worldwide. Known risk factors include age, gender, cigarettes, genetic factors, and other environmental influences . BC can be classified into non-muscle-invasive BC (NMIBC) and muscle-invasive BC (MIBC) . MIBC exhibits a more aggressive nature, correlates with a higher level of T-stage, and has more significant genetic heterogeneity . Despite comprehensive treatment regimens comprising neoadjuvant chemotherapy, radical cystectomy (RC) and adjuvant immunotherapies, a significant proportion of MIBC patients continue to progress to more advanced stages with limited clinical indicators. Unfortunately, the mechanisms underlying BC initiation, proliferation, and progression remain largely unknown. The occurrence of genetic alterations is believed to be closely linked to BC tumorigenesis. Therefore, investigating the genetic alterations might offer opportunities to further understand biological changes in BC . A key mechanism underlying tumor progression and metastasis is the epithelial-mesenchymal transition (EMT), which is associated with increased invasiveness, chemoresistance, and immune evasion. EMT is characterized by the downregulation of epithelial markers such as E-cadherin (CDH1) and the upregulation of mesenchymal markers like N-cadherin (CDH2), vimentin, Snail, and ZEB proteins . Emerging evidence suggests that junctional adhesion molecule 3 (JAM3) plays a role in EMT and cancer progression, with documented involvement in gastric cancer. However, its significance in MIBC remains poorly understood. Investigating JAM3 expression in MIBC may provide novel prognostic insights and help refine patient stratification for NAC and immunotherapy. Aim: This study aims to analyze JAM3 expression in transurethral biopsies from MIUC patients and correlate it with:

• Tumor aggressiveness (grading, staging, and histological features).
• Response to neoadjuvant chemotherapy .
• Patient survival and disease progression. This study will provide a better understanding of JAM3's role in EMT and MIUC progression, offering potential biomarker-driven insights for treatment stratification. If JAM3 is validated as a prognostic factor, it could guide personalized therapeutic approaches and optimizing NAC outcomes.

Conditions

Urothelial Carcinoma Bladder

Outcome Measures

Primary Outcomes (1)

• The response to neoadjuvant chemotherapy in muscle invasive bladder cancer in relation to JAM3 expression

  from enrollment to the end of treatment at 5 months

Interventions

junctional adhesion molecule3 expression by immunhistochemistry OTHER

* Data record of patient will be reviewed for the following: * Clinical features: * Age * Performance status * Risk factors(smoking,stones or bilharziasis) * Comorbidities * Family history * Pathological features: * Histological subtype * Grade * Muscle invasion * Carcinoma in situ * Immunohistochemistry(IHC): JAM3 expression by IHC * TNM staging * Number of chemotherapy cycles received * Radical surgery or * CCRT and type of concurrent * Post treatment histological response * . Follow-Up and Survival Analysis: * During treatment: Monitoring for adverse events of chemotherapy and clinical response. * After treatment: Imaging and clinical examination every 3 months for 2 years. * Correlation of JAM3 expression with progression-free survival (PFS) and overall survival (OS)..

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

:Patients diagnosed with muscle invasive urothelial carcinoma( MIUC) and eligible for neoadjuvant chemotherapy( NAC)

You may qualify if:

• Patients above 18 years
• Histopathological confirmed TCC
• Patients with MIBC
• Patients eligible for neoadjuvant chemotherapy

You may not qualify if:

• Patients with metastatic disease
• Patients ineligible for systemic therapy

Sponsors & Collaborators

• Zeinab Yahia Zaki: lead

Related Publications (1)

• Steiner L, Eldh M, Offens A, Veerman RE, Johansson M, Hemdan T, Netterling H, Huge Y, Abdul-Sattar Aljabery F, Alamdari F, Liden O, Sherif A, Gabrielsson S. Protein profile in urinary extracellular vesicles is a marker of malignancy and correlates with muscle invasiveness in urinary bladder cancer. Cancer Lett. 2025 Jan 28;609:217352. doi: 10.1016/j.canlet.2024.217352. Epub 2024 Nov 23.

  PMID: 39586489 BACKGROUND

Central Study Contacts

zienab yahia

CONTACT

20 01060399770; zienab959@gmail.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 2 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: zeinab yahia zaki

Study Record Dates

• First Submitted: March 24, 2025
• First Posted: March 30, 2025
• Study Start: October 1, 2025
• Primary Completion (Estimated): October 1, 2027
• Study Completion (Estimated): October 1, 2028
• Last Updated: March 30, 2025

Record last verified: 2025-03